Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026

Published by KuicK Research Product code 989755
Published Content info 360 Pages
Delivery time: 1-2 business days
Price
Back to Top
US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026
Published: February 17, 2021 Content info: 360 Pages
Description

"US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" Report Highlights:

  • US HIV Infection Drugs Market & Clinical Trial Insight
  • Comprehensive Insight On Approved HIV Infection Drugs Price & Dosage Analysis For US Market
  • HIV Infection Drugs Patent Timeline
  • Dosage, Formulation, Patent, Pricing Insight by Drug Class
  • 360 Page Data & Analysis On All Approved Drugs In Market

Pharmaceutical opportunities in the US related with HIV drug market is observed to be growing subsequently with time. The momentum that the US has shown towards the HIV treatment is making the market a super growth attainer. Hundreds of therapies available have remained successful in opening up novel windows for harnessing immediate actions on controlling CD4+ T cells in the human body. Although the US HIV drug market hasn't achieved a complete treatment regimen for the patients but the efficiency with which the US researchers have delivered specific drugs and therapies that could deliver better healthcare condition is magnificent when compared with other emerged markets of the world that are still adjusting to the mutative nature of the virus. It is observed for US HIV drug market that the research and development activities found in the country is believed to be providing extensive emphasis on the market acceptance and expansion at a large scale in short period of time.

The US HIV drug market will exceed billion dollars by the next few years at exponential compound annual growth rate. The prominent key drivers of the market are estimated to continue expanding in the US. One of the prominent reasons for the topline growth rate in the US is the high exchange rate dynamics and favorable dynamics for high potent antiretrovirals. For the expansion of the HIV drug market in the US, the total invoice spending is also increasing at a high compound annual growth rate. In addition to this, the net manufacturer revenue generated by HIV drug market is also expected to grow by a high percentage. As per the research conducted, the overall spending for the market growth is driven by high range of factors including increased rate of novel product uptake.

In the US, technology development is also a potential democratizing force, which is further enabling major key players in the US to enter the market. For boosting the overall market, bio-pharmaceutical companies are also increasingly including several patient centric approaches and strategies to drive certain organizational changes in the market and at last build a market capable of transducing potential healthcare benefits that could make the lives of the HIV infected patients better when compared with markets of the world.

As per "US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report findings it is concluded that the research and development pipelines for HIV drugs are growing at a high rate and on the brighter note, the success rate associated with the available antiretrovirals are continuing to expand at historic levels. Nevertheless, this is boosting the researchers to build an overall strong frame for clinical activity and ultimately result in novel product launches in the upcoming years. It is estimated that the future novel products developed in the US bio-pharmaceutical companies and research center will also contribute largely to the average market growth rate. The research report prepared delivers an insight for the US HIV drug market, which includes the growth areas as well as the channel perspective. In the research report, the impacts of the novel drug launches are described over the traditional drugs. In addition to it, the market research report also highlights several segments to watch in the next few years for their impact on the overall growth of the market and the consumption rate.

Table of Contents

Table of Contents

1. US HIV Drugs Market - Prevalence & Statistics

2. US HIV Drugs Market Overview

  • 2.1 Current Market Scenario
  • 2.2 Clinical Trials Landscape

3. US Nucleoside Reverse Transcriptase Inhibitors (NRTIs) - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 3.1 Abacavir (Ziagen)
  • 3.2 Emtricitabine (Emtriva)
  • 3.3 Lamivudine (Epivir)
  • 3.4 Tenofovir Disoproxil Fumarate (Viread)
  • 3.5 Zidovudine (Retrovir)
  • 3.6 Stavudine (Zerit)
  • 3.7 Didanosine (Videx/Videx EC)

4. US Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 4.1 Doravirine (Pifeltro)
  • 4.2 Efavirenz (Sustiva)
  • 4.3 Etravirine (Intelence)
  • 4.4 Rilpivirine (Edurant)
  • 4.5 Nevirapine (Viramune/Viramune XR)

5. US Protease Inhibitors (PIs) - Branded & Generic Availability, Dosage, Patent, & Price Analysis

  • 5.1 Atazanavir (Reyataz)
  • 5.2 Darunavir (Prezista)
  • 5.3 Fosamprenavir (Lexiva)
  • 5.4 Ritonavir (Norvir)
  • 5.5 Saquinavir (Invirase)
  • 5.6 Tipranavir (Aptivus)
  • 5.7 Nelfinavir (Viracept)
  • 5.8 Amprenavir (Agenerase)
  • 5.9 Indinavir (Crixivan)

6. US Fusion Inhibitors - Branded & Generic Availability, Dosage, Patent, & Price Analysis

  • 6.1 Enfuvirtide (Fuzeon)

7. US CCR5 Antagonists - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 7.1 Maraviroc (Selzentry)

8. US Integrase Inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 8.1 Dolutegravir (Tivicay)
  • 8.2 Raltegravir (Isentress/Isentress HD)

9. US Attachment Inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 9.1 Ibalizumab-Uiyk (Trogarzo)
  • 9.2 Fostemsavir (Rukobia)

10. US Pharmacokinetic Enhancers - Availability, Dosage, Patent & Price Analysis

  • 10.1 Cobicistat (Tybost)

11. US Combinational HIV Drugs - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 11.1 Abacavir/Lamivudine (Epzicom)
  • 11.2 Abacavir/Dolutegravir/Lamivudine (Triumeq)
  • 11.3 Abacavir/Lamivudine/Zidovudine) Trizivir
  • 11.4 Atazanavir/Cobicistat (Evotaz)
  • 11.5 Bictegravir/ Emtricitabine/ Tenofovir Alafenamide (Biktarvy)
  • 11.6 Cobicistat/Darunavir (Prezcobix)
  • 11.7 Cobicistat/Darunavir/Emtricitabine/Tenofovir (Symtuza)
  • 11.8 Dolutegravir/Lamivudine (Dovato)
  • 11.9 Dolutegravir/Rilpivirine (Juluca)
  • 11.10 Doravirine/Lamivudine/Tenofovir (Delstrigo)
  • 11.11 Efavirenz/Emtricitabine/Tenofovir (Atripla)
  • 11.12 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi/Simfi Lo)
  • 11.13 Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (Genvoya)
  • 11.14 Cobicistat/ Elvitegravir/ Emtricitabine/ Tenofovir (Stribild)
  • 11.15 Emtricitabine/ Rilpivirine/ Tenofovir Alafenamide (Odefsey)
  • 11.16 Emtricitabine/Rilpivirine/Tenofovir (Complera)
  • 11.17 Emtricitabine/Tenofovir Alafenamide (Descovy)
  • 11.18 Emtricitabine/Tenofovir (Truvada)
  • 11.19 Lamivudine/Tenofovir
  • 11.20 Lamivudine/Zidovudine (Combivir)
  • 11.21 Lopinavir/Ritonavir (Kaletra)
  • 11.22 Cabotegravir/Rilpivirine (Cabenuva)
  • 11.23 Emtricitabine / Nelfinavir / Tenofovir Oral Kit
  • 11.24 Emtricitabine / Lopinavir / Ritonavir / Tenofovir Oral Kit

12. Compititive Landscape

  • 12.1 AbbVie
  • 12.2 AstraZeneca plc
  • 12.3 Boehringer Ingelheim
  • 12.4 Bristol Myers Squibb
  • 12.5 Gilead
  • 12.6 GlaxoSmithKline plc
  • 12.7 Janssen Pharmaceuticals
  • 12.8 Merck
  • 12.9 Pfizer
  • 12.10 Roche
  • 12.11 Sun Pharma
  • 12.12 ViiV Healthcare

List of Figures

  • Figure 1-1: US - Number of HIV Cases (Million), 2012, 2014 & 2018
  • Figure 1-2: US - Estimated Number of HIV Cases (Million), 2020, 2025 & 2030
  • Figure 1-3: US - Number of Newly Diagnosed HIV Cases & Deaths, 2018
  • Figure 1-4: US - Estimated Number of Newly Diagnosed HIV Cases, 2018, 2020 & 2025
  • Figure 1-5: US - Estimated Number of HIV Deaths, 2018, 2020 & 2025
  • Figure 1-6: US - HIV Incidence Rate (Per 100'000), 2014, 2018 & 2020
  • Figure 1-7: US - HIV Incidence Rate by Age Group (Per 100'000), 2018
  • Figure 1-8: US - HIV Incidence Rate by Race (Per 100'000), 2018
  • Figure 1-9: US - HIV Incidence Rate by Gender (Per 100'000), 2018
  • Figure 1-10: US - HIV Cases by Mode of Transmission (%), 2018
  • Figure 1-11: US - Percentage of HIV Patients by Nature of Treatment (%), 2018
  • Figure 2-1: Global - HIV Drug Market Opportunity (US$ Billion), 2020 - 2026
  • Figure 2-2: Global - HIV Drug Market Size by Region (US$ Billion), 2020
  • Figure 2-3: Global - HIV Drug Market Size by Region (US$ Billion), 2020
  • Figure 2-4: North America - HIV Drug Market Size US v/s Others (US$ Billion), 2020
  • Figure 2-5: US - HIV Drug Market Opportunity (US$ Billion), 2020 - 2026
  • Figure 2-6: US - Number of HIV Infection Drug Clinical Pipeline by Phase, 2021 - 2026
  • Figure 2-7: US - Number of HIV Infection Drugs in Clinical Pipeline by Drug Class, 2021 - 2026
  • Figure 2-8: US - Number of HIV Infection Drugs in Clinical Pipeline by Organization, 2021 - 2026
  • Figure 2-9: US - Number of HIV Infection Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026
  • Figure 3-1: Ziagen - FDA Approval & First Generic Approval Year
  • Figure 3-2: Ziagen Oral Solution - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 3-3: Ziagen Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-4: Generic Abacavir Oral Solution - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 3-5: Generic Abacavir Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-6: Ziagen - Daily Treatment Cost by Dosage Form (US$)
  • Figure 3-7: Ziagen - Pediatric Dosage form by Weight (mg/day)
  • Figure 3-8: Emtriva - FDA Approval Year by Dosage Form
  • Figure 3-9: US - Emtriva Patent Issue & Expiration Year
  • Figure 3-10: Emtriva Oral Solution - Price for 170ml Supply & Price Per ml (US$), February'2021
  • Figure 3-11: Emtriva Tablet - Price for 30 Capsules & Price Per Unit Capsule (US$), February'2021
  • Figure 3-12: Emtriva - Daily Dose by Dosage Form (mg)
  • Figure 3-13: Emtriva: Daily Treatment Cost by Dosage Form (US$), February'2021
  • Figure 3-14: Epivir: FDA Approval Year by Dosage Form
  • Figure 3-15: Epivir: First Generic Approval Year by Dosage Form
  • Figure 3-16: Epivir Oral Solution - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 3-17: Epivir 150mg Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-18: Epivir 300mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-19: Generic Lamivudine Oral Solution - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 3-20: Generic Lamivudine 150mg Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-21: Generic Lamivudine 150mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-22: Generic Lamivudine 150mg Tablet - Price for 50 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-23: Generic Lamivudine 300mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 3-24: Epivir: Daily Treatment Cost by Dosage Form (US$), February'2021
  • Figure 3-25: Epivir - Pediatric Dosage form by Weight (mg/day)
  • Figure 3-26: Viread - FDA Approval Year by Dosage Form
  • Figure 3-27: Viread - First Generic Approval Year by Dosage Form
  • Figure 3-28: Viread Oral Powder - Price for 60 gm Supply & Price Per gm (US$), Februray'2021
  • Figure 3-29: Viread 300 mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), Februray'2021
  • Figure 3-30: Viread Tablet - Price for 30 Tablets of 150,200 & 250mg Dose & Price Per Unit Tablet (US$), Februray'2021
  • Figure 3-31: Generic Viread 300 mg Tablet - Average Price for 28 Tablets & Price Per Unit Tablet (US$), Februray'2021
  • Figure 3-32: Generic Viread 300 mg Tablet - Average Price for 30 Tablets & Price per Unit Tablet (US$), Februray'2021
  • Figure 3-33: Generic Viread 300 mg Tablet - Average Price for 60 Tablets & Price Per Unit Tablet (US$), Februray'2021
  • Figure 3-34: Generic Viread 300 mg Tablet - Average Price for 90 Tablets & Price Per Unit Tablet (US$), Februray'2021
  • Figure 3-35: Generic Viread 300 mg Tablet - Average Price for 180 Tablets & Price Per Unit Tablet (US$), Februray'2021
  • Figure 3-36: Viread Tablet - Pediatric Dose by Weight (mg/day)
  • Figure 3-37: Viread Oral Powder - Pediatric Dosage form by Weight (mg/day)
  • Figure 3-38: Viread - Daily Treatment Cost by Dosage Form (US$), February'2021
  • Figure 3-39: Global - Viread Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 3-40: US - Viread Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 3-41: Global - Viread Annual Sales Value by Region (US$ Million), 2020
  • Figure 3-42: Global - Viread Annual Sales Value by Region (%), 2020
  • Figure 3-43: Global - Viread Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 3-44: US - Viread Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 3-45: Retrovir - FDA Approval Year by Dosage Form
  • Figure 3-46: Retrovir - First Generic Approval Year by Dosage Form
  • Figure 3-47: Retrovir Intravenous Solution - Price for 100 ml Supply & Price Per ml (US$), February'2021
  • Figure 3-48: Retrovir Capsule - Price for 100 Capsules & Price Per Unit Capsule (US$), February'2021
  • Figure 3-49: Retrovir Syrup - Price for 240ml & Price Per ml (US$), February'2021
  • Figure 3-50: Generic Zidovudine Tablet - Price for 60 Tablets Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 3-51: Generic Zidovudine Capsule - Price for 100 Capsules & Price Per Unit Capsule (US$), February'2021
  • Figure 3-52: Generic Zidovudine Syrup - Price for 240ml & Price Per ml (US$), February'2021
  • Figure 3-53: Retrovir Capsule - Daily, Monthly & Annual Treatment Cost (US$), February'2021
  • Figure 3-54: Retrovir - Oral Pediatric Dosage form by Weight (mg/Kg/day)
  • Figure 3-55: Zerit - FDA & First Generic Approval Year
  • Figure 3-56: Zerit - FDA Approval Year by Dosage Forms
  • Figure 3-57: Zerit - Price for 60 Capsule Supply & Price Per Unit Capsule of 15mg Dose (US$), February'2021
  • Figure 3-58: Zerit - Price for 60 Capsule Supply & Price Per Unit Capsule of 20mg Dose (US$), February'2021
  • Figure 3-59: Zerit - Price for 60 Capsule Supply & Price Per Unit Capsule of 30mg Dose (US$), February'2021
  • Figure 3-60: Zerit - Price for 60 Capsules & Price Per Unit Capsule (US$), February'2021
  • Figure 3-61: Generic Stavudine - Price for 60 Capsules of Various Dose Regimens (US$), February'2021
  • Figure 3-62: Zerit - Daily Adult Dose by Weight (mg)
  • Figure 3-63: Zerit - Minimum & Maximum Daily Treatment Cost (US$), February'2021
  • Figure 3-64: Zerit - Pediatric Dose by Age (mg/kg Twice Daily)
  • Figure 3-65: Videx - FDA Approval Year by Dosage Form
  • Figure 3-66: Videx Oral Powder for Reconstitution - Price for 200ml Supply & Price Per ml (US$), February'2021
  • Figure 3-67: Videx EC - Price for 30 Capsule Supply & Price Per Unit Capsule (US$), February'2021
  • Figure 3-68: Generic Videx EC - Price for 30 Capsule Supply & Price Per Unit Capsule (US$), February'2021
  • Figure 3-69: Videx - Daily Adult Dose by Weight (mg)
  • Figure 3-70: Videx - Minimum & Maximum Daily Treatment Cost (US$), February'2021
  • Figure 3-71: Videx - Pediatric Dose by Age (mg/m2 Daily)
  • Figure 3-72: Videx - Adult Dose by Weight (mg)
  • Figure 4-1: Pifeltro - FDA Approval Year by Type of Therapy
  • Figure 4-2: US - Pifeltro Patent Issue & Expiration Year
  • Figure 4-3: Pifeltro - Price for 30 Capsules & Price Per Unit Capsule (US$), February'2021
  • Figure 4-4: Pifeltro - Recommended Dose by Type of Therapy (mg/day)
  • Figure 4-5: Sustiva - FDA Approval Year by Dosage Form
  • Figure 4-6: Sustiva - First Generic Approval Year by Dosage Form
  • Figure 4-7: Sustiva Capsules - Price for 30 Capsule Supply & Price Per Unit Capsule of 50mg Dose (US$), February'2021
  • Figure 4-8: Sustiva Capsules - Price for 90 Capsule Supply & Price Per Unit Capsule of 200mg Dose (US$), February'2021
  • Figure 4-9: Sustiva Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 4-10: Generic Efavirenz Capsules - Price for 30 Capsule Supply & Price Per Unit Capsule of 50mg Dose (US$), February'2021
  • Figure 4-11: Generic Efavirenz Capsules - Price for 90 Capsule Supply & Price Per Unit Capsule of 200mg Dose (US$), February'2021
  • Figure 4-12: Generic Efavirenz Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 4-13: Sustiva - Recommended Adult Dose by Type of Therapy (mg/day), February'2021
  • Figure 4-14: Sustiva - Recommended Pediatric Dose by Weight (mg/day), February'2021
  • Figure 4-15: Intelence - FDA Approval Year by Dosage Form
  • Figure 4-16: US - Intelence Patent Issue & Expiration Year
  • Figure 4-17: Intelence - Price for 120 Tablets & Price Per Unit of 25mg & 100mg Tablet (US$), February'2021
  • Figure 4-18: Intelence - Price for 60 Tablets & Price Per Unit of 200mg Tablet (US$), February'2021
  • Figure 4-19: Intelence - Daily, Monthly & Annual treatment Cost (US$), February'2021
  • Figure 4-20: Intelence - Recommended Pediatric Dose by Weight (mg/day), February'2021
  • Figure 4-21: Edurant - Jassen's US Patent Issue & Expiration Year
  • Figure 4-22: Edurant - AstraZeneca's US Patent Issue & Expiration Year
  • Figure 4-23: Edurant - Price for 30 Tablet Supply & Price Per Unit Tablet of 25mg (US$), February'2021
  • Figure 4-24: Edurant - Daily Dose by Type of Therapy (mg), February'2021
  • Figure 4-25: Global - Edurant Annual Sales Value (US$ Million), 2016 - 2020
  • Figure 4-26: Global - Edurant Annual Sales Value (US$ Million), 2016 - 2020
  • Figure 4-27: Global - Edurant Annual Sales Value by Region (US$ Million), 2020
  • Figure 4-28: Global - Edurant Annual Sales Value by Region (%), 2020
  • Figure 4-29: Global - Edurant Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 4-30: US - Edurant Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 4-31: Viramune - FDA Approval Year by Dosage Form
  • Figure 4-32: Viramune - First Generic Approval by Dosage Form
  • Figure 4-33: Viramune Suspension - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 4-34: Viramune Tablet 200mg - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 4-35: Viramune XR Tablet 400mg - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 4-36: Generic Nevirapine Suspension - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 4-37: Generic Nevirapine Tablet 200mg - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 4-38: Generic Tablet 400mg - Price for 30 Tablets & Price Per Unit Tablet (US$), February'2021
  • Figure 4-39: Viramune - Oral Dose by Treatment Phase (mg/day), February'2021
  • Figure 4-40: Viramune - Recommended Pediatric Dose by Surface Area (mg/day), February'2021
  • Figure 5-1: Reyataz - FDA approval Year by Dosage Form
  • Figure 5-2: Reyataz Capsules - Price for 60 Capsule & Price Per Unit Capsule of 150 to 200mg (US$), February'2021
  • Figure 5-3: Reyataz Capsules - Price for 30 Capsule & Price Per Unit Capsule of 300mg (US$), February'2021
  • Figure 5-4: Reyataz Powder - Price for 30 Supply & Price Per Unit Oral Powder (US$), February'2021
  • Figure 5-5: Atazanavir Capsules - Price for 60 Capsule & Price Per Unit Capsule of 150 to 200mg (US$), February'2021
  • Figure 5-6: Atazanavir Capsules - Price for 30 Capsule & Price Per Unit Capsule of 300mg (US$), February'2021
  • Figure 5-7: Reyataz - Dose by Treatment Therapy (mg/day), February'2021
  • Figure 5-8: Reyataz - Recommended Pediatric Dose by Weight (mg/day), February'2021
  • Figure 5-9: Prezista - FDA approval Year by Dosage Form
  • Figure 5-10: US - Prezista Patent Issue & Expiration Year by Assignee
  • Figure 5-11: Prezista Suspension - Price for a Supply of 200ml & Price Per ml (US$), February'2021
  • Figure 5-12: Prezista Tablet - Price per unit of Various Doses (US$), February'2021
  • Figure 5-13: Reyataz - Dose by Type of HIV Patient (mg/day), February'2021
  • Figure 5-14: Reyataz - Daily Treatment Cost for Treatment Naïve Patients by Dosage Form (mg/day), February'2021
  • Figure 5-15: Lexiva - FDA approval Year by Dosage Form
  • Figure 5-16: Lexivia Suspension - Price for a Supply of 225ml & Price Per ml (US$), February'2021
  • Figure 5-17: Lexivia Tablet - Price for 60 Tablet Supply & Price Per Unit (US$), February'2021
  • Figure 5-18: Generic Fosamprenavir Tablet - Price for 60 Tablet Supply & Price Per Unit (US$), February'2021
  • Figure 5-19: Lexivia - Dose by Treatment Therapy (mg/day), February'2021
  • Figure 5-20: Lexivia - Recommended Pediatric Dose by Weight (mg/Kg Twice daily), February'2021
  • Figure 5-21: Norvir - FDA approval Year by Dosage Form
  • Figure 5-22: US - Norvir Patent Issue & Expiration Year
  • Figure 5-23: Norvir Powder - Price for a Supply of 30 Powders & Price Per Unit (US$), February'2021
  • Figure 5-24: Norvir Tablet - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 5-25: Norvir Solution - Price for 240ml Supply & Price Per ml (US$), February'2021
  • Figure 5-26: Generic Ritonavir Tablet - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 5-27: Norvir - Daily Treatment Cost by Dosage Form (US$), February'2021
  • Figure 5-28: Norvir - FDA approval Year by Dosage Form
  • Figure 5-29: Invirase Tablet - Price for 120 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 5-30: Invirase Tablet - Daily Dose During Initial 7 days v/s After 7 Days (mg/day), February'2021
  • Figure 5-31: Invirase Tablet - Daily Treatment Cost During Initial Week v/s After Initial Week (mg/day), February'2021
  • Figure 5-32: Aptivus - FDA approval Year by Dosage Form
  • Figure 5-33: Aptivus - Price for 120 Capsule Supply & Price Per Unit Capsule (US$), February'2021
  • Figure 5-34: Aptivus Solution - Price for 95ml Supply & Price Per ml (US$), February'2021
  • Figure 5-35: Aptivus - Daily Treatment Cost by Dosage Form (US$), February'2021
  • Figure 5-36: Viracept - FDA approval Year by Dosage Form
  • Figure 5-37: Viracept - Price for a Supply of 300 Tablets & Price Per Unit Tablet of 250mg (US$), February'2021
  • Figure 5-38: Viracept - Price for a Supply of 120 Tablets & Price Per Unit Tablet of 625mg (US$), February'2021
  • Figure 5-39: Viracept - Daily Minimum & Maximum Dose (mg), February'2021
  • Figure 5-40: Viracept Tablet - Daily Minimum & Maximum Treatment Cost (US$), February'2021
  • Figure 5-41: Agenerase - FDA Approval & Patent Expiration Year
  • Figure 5-42: Agenerase - Price for 480 Capsule Supply & Price Per Unit Capsule of 50 mg (US$), February'2021
  • Figure 5-43: Agenerase - Recommended Dose by Type of Therapy (mg), February'2021
  • Figure 5-44: Crixivan - FDA approval Year by Dosage Form
  • Figure 5-45: Crixivan - Patent Issue & Expiration Year
  • Figure 5-46: Crixivan - Price for a Supply of 360 Capsules & Price Per Unit Capsules of 200mg (US$), February'2021
  • Figure 5-47: Crixivan - Price for a Supply of 180 Capsules & Price Per Unit Capsules of 400mg (US$), February'2021
  • Figure 5-48: Crixivan - Recommended Dose by Therapy Type (mg/day), February'2021
  • Figure 5-49: Crixivan - Average cost of Single Dose & Daily Treatment Cost (US$), February'2021
  • Figure 6-1: US - Fuzeon Patent Issue & Expiration Year
  • Figure 6-2: Fuzeon - Price for a Supply of 60 Powders & Price Per Unit of 90mg Powder (US$), February'2021
  • Figure 6-3: Fuzeon - Cost of Daily, Monthly & Annual Treatment (US$), February'2021
  • Figure 7-1: Selzentry - FDA approval Year by Dosage Form
  • Figure 7-2: US - Selzentry Patent Issue & Expiration Year
  • Figure 7-3: Selzentry Oral Liquid - Price for a Supply of 230 ml & Price Per ml of 90mg (US$), February'2021
  • Figure 7-4: Selzentry Tablets - Price for a Supply of 120 Tablets & Price Per Unit of 25mg & 75mg Tablet (US$), February'2021
  • Figure 7-5: Selzentry Tablets - Price for a Supply of 120 Tablets & Price Per Unit of 150mg & 300mg Tablet (US$), February'2021
  • Figure 7-6: Selzentry - Daily Dose by Combination Agent (mg), February'2021
  • Figure 7-7: Selzentry - Daily Pediatric Dose in Combination in Combination with Potent CYP450 3A Inhibitors by Weight (mg), February'2021
  • Figure 7-8: Global - Selzentry Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 7-9: US - Selzentry Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 7-10: Selzentry - Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 7-11: Selzentry - Annual Sales Value by Region (%), 2020
  • Figure 7-12: Global - Selzentry Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 7-13: US - Selzentry Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 8-1: Tivicay - FDA approval Year by Dosage Form
  • Figure 8-2: US - Tivicay Patent Issue & Expiration Year
  • Figure 8-3: Tivicay - Price for a Supply of 30 Tablets & Price Per Unit Tablet of Various Doses (US$), February'2021
  • Figure 8-4: Tivicay - Minimum & Maximum Daily Dose (mg), February'2021
  • Figure 8-5: Tivicay - Minimum & Maximum Daily Treatment Cost (US$), February'2021
  • Figure 8-6: Tivicay - Pediatric Dose by Weight of Patient (mg), February'2021
  • Figure 8-7: Global - Tivicay Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 8-8: Global - Tivicay Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 8-9: Global - Tivicay Annual Sales Value by Region (%), 2020
  • Figure 8-10: Global - Tivicay Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 8-11: US - Tivicay Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 8-12: Isentress - FDA approval Year by Dosage Form
  • Figure 8-13: Isentress - Istituto Di Ricerche Di Biologia Molecolare's Patent Issue & Expiration Year
  • Figure 8-14: Isentress - Merck's Patent Issue & Expiration Year
  • Figure 8-15: Isentress - Price for 60 Granule Supply & Price Per Unit of 100mg Granules (US$), February'2021
  • Figure 8-16: Isentress - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 8-17: Isentress - Price for a Supply of 60 Chewable Tablets & Price Per Unit Tablet of Various Doses (US$), February'2021
  • Figure 8-18: Isentress HD - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 8-19: Isentress - Recommended Dose by Patient Type (mg/day), February'2021
  • Figure 8-20: Global - Isentress/Isentress HD Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 8-21: Global - Isentress Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 9-1: Trogarzo - FDA Approval & Patent Expiration Year
  • Figure 9-2: Trogarzo - Price for 2.66ml Supply & Price Per ml of Intravenous Solution (US$), February'2021
  • Figure 9-3: Trogarzo - Loading Dose v/s Maintenance Dose (mg/2 Weeks), February'2021
  • Figure 9-4: Trogarzo - Cost of Loading Dose v/s Maintenance Dose (US$), February'2021
  • Figure 9-5: Global - Trogarzo Annual Sales (US$ Million), 2018 & 2019
  • Figure 9-6: US - Rukobia Patent Issue & Expiration Year
  • Figure 9-7: Rukobia - Price for 60 Tablets Supply & Price Per Unit of 600mg Tablet (US$), Februray'2021
  • Figure 9-8: Rukobia - Cost of Daily & Monthly Treatment (US$), Februray'2021
  • Figure 10-1: US - Tybost Patent Issue & Expiration Year
  • Figure 10-2: Tybost - Price for 30 Tablets Supply & Price Per Unit of 150mg (US$), February'2021
  • Figure 11-1: Epzicom - FDA Approval & First Generic Approval
  • Figure 11-2: Epzicom - Price for 30 Tablets Supply & Price per unit Tablet (US$), February'2021
  • Figure 11-3: Generic Abacavir/Lamivudine - Price for 30 Tablets Supply & Price Per Unit of 150mg (US$), February'2021
  • Figure 11-4: Epzicom - Daily, Monthly & Annual Treatment Cost (US$), February'2021
  • Figure 11-5: Global - Epzicom/Kivexa Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 11-6: US - Epzicom/Kivexa Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 11-7: Epzicom/Kivexa - Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 11-8: Epzicom/Kivexa - Annual Sales Value by Region (%), 2020
  • Figure 11-9: Global - Epzicom/Kivexa Quarterly Sales Value (US$ Million), 2020
  • Figure 11-10: US - Triumeq Patent Issue & Expiration Year
  • Figure 11-11: Epzicom - Price for 30 Tablets Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-12: Global - Triumeq Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-13: US - Triumeq Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 11-14: Triumeq - Annual Sales Value by Region (%), 2020
  • Figure 11-15: Global - Triumeq Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 11-16: US - Triumeq Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 11-17: Trizivir - FDA Approval & First Generic Approval
  • Figure 11-18: Trizivir - Price for 60 Tablets Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-19: Generic Trizivir - Price for 60 Tablets Supply & Price Per Unit of 150mg (US$), February'2021
  • Figure 11-20: Trizivir - Daily, Monthly & Annual Treatment Cost (US$), February'2021
  • Figure 11-21: US - Evotaz Patent Issue & Expiration Year
  • Figure 11-22: Evotaz - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-23: Biktarvy - Gilead's US Patent Issue & Expiration Year
  • Figure 11-24: Biktarvy - Emory's US Patent Issue & Expiration Year
  • Figure 11-25: Biktarvy - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-26: Global - Biktarvy Annual Sales Value (US$ Billion), 2018 - 2020
  • Figure 11-27: Global - Biktarvy Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-28: Biktarvy - Annual Sales Value by Region (%), 2020
  • Figure 11-29: Global - Biktarvy Quarterly Sales Value (US$ Million), 2019 - 2020
  • Figure 11-30: US - Biktarvy Quarterly Sales Value (US$ Million), 2019 - 2020
  • Figure 11-31: Prezcobix - Gilead's US Patent Issue & Expiration Year
  • Figure 11-32: Prezcobix - Tibotic's US Patent Issue & Expiration Year
  • Figure 11-33: Prezcobix - Janssen's US Patent Issue & Expiration Year
  • Figure 11-34: Prezcobix - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-35: Symtuza - Gilead's US Patent Issue & Expiration Year
  • Figure 11-36: Symtuza - Emory's US Patent Issue & Expiration Year
  • Figure 11-37: Symtuza - Tibotic's US Patent Issue & Expiration Year
  • Figure 11-38: Symtuza - Janssen's US Patent Issue & Expiration Year
  • Figure 11-39: Symtuza - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-40: Dovato - GSK's US Patent Issue & Expiration Year
  • Figure 11-41: Dovato - VIIV's US Patent Issue & Expiration Year
  • Figure 11-42: Dovato - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-43: Global - Dovato Annual Sales Value by Region (US$/GBP Million), 2019 &2020
  • Figure 11-44: US - Dovato Annual Sales Value by Region (US$/GBP Million), 2019 & 2020
  • Figure 11-45: Dovato - Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 11-46: Dovato - Annual Sales Value by Region (%), 2020
  • Figure 11-47: Global - Dovato Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 11-48: US - Dovato Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 11-49: US - Juluca Number of Patent Issued by Assignee Name
  • Figure 11-50: US - Juluca Patent Expiration Year by Assignee
  • Figure 11-51: Juluca - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-52: Global - Juluca Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 11-53: US - Juluca Annual Sales Value (US$/GBP Million), 2017 - 2020
  • Figure 11-54: Juluca - Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 11-55: Juluca - Annual Sales Value by Region (%), 2020
  • Figure 11-56: Global - Juluca Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 11-57: US - Juluca Quarterly Sales Value (US$/GBP Million), 2020
  • Figure 11-58: US - Delstrigo Patent Issue & Expiration Year
  • Figure 11-59: Delstrigo - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-60: Delstrigo - Daily, Monthly & Annual Treatment Cost (US$), February'2021
  • Figure 11-61: Atripla - FDA approval & Generic Approval Year
  • Figure 11-62: Alripla - Gilead's US Patent Issue & Expiration Year
  • Figure 11-63: Atripla - Emory's US Patent Issue & Expiration Year
  • Figure 11-64: Atripla - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-65: Generic Atripla - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-66: Global - Atripla Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-67: US - Atripla Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-68: Atripla - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-69: Atripla - Annual Sales Value by Region (%), 2020
  • Figure 11-70: Global - Atripla Quarterly Sales Value (US$ Million), 2020
  • Figure 11-71: US - Atripla Quarterly Sales Value (US$ Million), 2020
  • Figure 11-72: Simfi/Simfi Lo - FDA approval Year
  • Figure 11-73: Simfi/Simfi Lo - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-74: Genvoya - Number of US Patent Issued by Assignee Name
  • Figure 11-75: Genvoya - US Patent Expiration Year by Assignee
  • Figure 11-76: Genvoya - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-77: Global - Genvoya Annual Sales Value (US$ Billion), 2017 - 2020
  • Figure 11-78: US - Genvoya Annual Sales Value (US$ Billion), 2017 - 2020
  • Figure 11-79: Genvoya - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-80: Genvoya - Annual Sales Value by Region (%), 2020
  • Figure 11-81: Global - Genvoya Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-82: US - Genvoya Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-83: Stribild - Number of US Patent Issued by Assignee Name
  • Figure 11-84: US - Stribild Patent Expiration Year by Assignee
  • Figure 11-85: Stribild - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-86: Global - Stribild Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-87: US - Stribild Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-88: Stribild - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-89: Stribild - Annual Sales Value by Region (%), 2020
  • Figure 11-90: Global - Stribild Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-91: US - Stribild Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-92: Odefsey - Number of US Patent Issued by Assignee Name
  • Figure 11-93: US - Odefsey Patent Expiration Year by Assignee
  • Figure 11-94: Odefsey - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-95: Global - Odefsey Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-96: Global - Odefsey Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-97: Odefsey - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-98: Odefsey - Annual Sales Value by Region (%), 2020
  • Figure 11-99: Global - Odefsey Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-100: US - Odefsey Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-101: Complera - Number of US Patent Issued by Assignee Name
  • Figure 11-102: Complera - US Patent Expiration Year by Assignee
  • Figure 11-103: Complera - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-104: Complera - Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-105: Complera - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-106: Complera - Annual Sales Value by Region (%), 2020
  • Figure 11-107: Global - Complera Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-108: US - Complera Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-109: Descovy - Number of US Patents Issued by Assignee Name
  • Figure 11-110: Descovy - US Patent Expiration Year by Assignee
  • Figure 11-111: Descovy - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-112: Descovy - Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-113: Descovy - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-114: Descovy - Annual Sales Value by Region (%), 2020
  • Figure 11-115: Global - Descovy Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-116: US - Descovy Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-117: Truvada - Number of US Patent Issued by Assignee Name
  • Figure 11-118: US - Descovy Patent Expiration Year by Assignee
  • Figure 11-119: Truvada: Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-120: Truvada - Annual Sales Value (US$ Million), 2017 - 2020
  • Figure 11-121: Truvada - Annual Sales Value by Region (US$ Million), 2020
  • Figure 11-122: Truvada - Annual Sales Value by Region (%), 2020
  • Figure 11-123: Global - Truvada Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-124: US - Truvada Quarterly Sales Value (US$ Million), 2019 & 2020
  • Figure 11-125: Cimduo - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-126: Temixys - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-127: Combivir - FDA & First Generic Approval Year
  • Figure 11-128: Combivir - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 11-129: Generic Combivir - Price for various Supplies of Oral Tablet (US$), February'2021
  • Figure 11-130: Kaletra - FDA Approval Year by Dosage Form
  • Figure 11-131: Kaletra Oral Solution - Branded v/s Generic Price for 160 ml Supply & Price Per ml of (US$), February'2021
  • Figure 11-132: Kaletra Oral Tablet - Price for 60 Tablet & Price per unit Tablets of 100mg-25mg Dose (US$), February'2021
  • Figure 11-133: Kaletra Oral Tablet - Price for 12 Tablet & 120 Tablet Supply of 200mg-50mg Dose (US$), February'2021
  • Figure 11-134: Cabenuva - Price for Various Supplies of Cabenuva Suspension Kit (US$), February'2021
  • Figure 11-135: Cabenuva - Recommended Initial & Subsequent Dose (mg/Month),
  • Figure 11-136: Emtricitabine / Nelfinavir / Tenofovir Oral Kit - Price Per Unit by Product (US$), February'2021
  • Figure 11-137: Emtricitabine / Nelfinavir / Tenofovir Oral Kit - Price Per Unit by Product (US$), February'2021
Back to Top